Abstract 17747: Low Apolipoprotein A1 Predicts 10year-Cardiovascular Mortality in Patients Undergoing Percutaneous Coronary Intervention With or Without Statin Therapy, a Possible Useful Biomarker and Residual Therapeutic Target in the Statin Era

Despite pharmacotherapeutic interventions targeting LDL-cholesterol (LDL-C) by statins, cardiovascular mortality remains high in patients with coronary artery disease (CAD). Parameters of lipoproteins (apolipoprotein (Apo) B100, Apo A1 and their ratio) were previously demonstrated to offer better prognostic value for adverse outcomes in patients with acute coronary syndromes (ACS). However, its clinical utility for long-term prognosis is not fully established. This study thus aimed to address prognostic implication of apolipoproteins in patients with stable CAD, as well as ACS. Methods and results: This is a retrospective analysis of a single-center prospective database consisting 3831 patients undergone PCI since 1984 to 2010. The present study enrolled 2170 patients whose data of both ApoA1 and ApoB are available, including 604 ACS patients (27.8%). Median follow-up period was 6.89 years (range: 0.01-10.9 years). Multivariate analysis using Cox proportional hazard model demonstrated low ApoA1 (1st quart...